OMER - Omeros reports positive data for rare blood disorder candidate

2023-04-25 10:15:15 ET

• Shares of Omeros Corporation ( NASDAQ: OMER ) spiked in early trading Tuesday after announcing Phase 1 results for OMS906, its candidate for patients with rare hematological disease paroxysmal nocturnal hemoglobinuria (PNH).
• Citing an interim analysis from its ongoing Phase 1b trial, Omeros ( OMER ) said that OMS906 led to statistically significant and clinically meaningful improvements in PNH patients for all markers it considered for hemolysis, including hemoglobin (Hgb) and lactate dehydrogenase (LDH).
• The single-arm, open-label trial had so far enrolled nine PNH patients who received once-monthly subcutaneous administration of OMS906. All patients were complement-inhibitor-treatment naïve and received only the lowest subcutaneous dose of OMS906.
• According to the company, the experimental therapy was well tolerated generating safety data in line with Phase 1 safety observations.
• Read why Seeking Alpha analyst BiotechValley Insights reaffirmed their Strong Buy rating on OMER.

For further details see: